Just In
HCL FY26 Guidance: Revenue growth expected to be between 3.0%-5.0% YoY in CC
HCL reported revenue of $3,545 million in USD terms, marking a 1.3% increase QoQ and 5.4% growth YoY
HCL's revenue in constant currency declined 0.8% quarter-on-quarter but grew 3.7% year-on-year
HCL FY26 Guidance: Revenue growth expected to be between 3.0%-5.0% YoY in CC
HCL reported revenue of $3,545 million in USD terms, marking a 1.3% increase QoQ and 5.4% growth YoY
HCL's revenue in constant currency declined 0.8% quarter-on-quarter but grew 3.7% year-on-year

Kiran Mazumdar Shaw

(39 search results)

Biocon developing 20 biosimilar products for global markets
Lift Covid restrictions, allow people to get back to life: Mazumdar-Shaw
Covid-19 is an endemic, not pandemic: Mazumdar-Shaw
Mix and match vaccines, says Kiran Mazumdar-Shaw
Syngene’s winning formula

Syngene’s winning formula

Budget 2021: Research, innovation get a boost
SC agrees to amend order making Covid-19 tests free
Fortune India 500: Why are there so few women leaders?
MPW Summit 2019: Celebrating women power
Biocon’s biologics portfolio comes into its own
Healthcare's missing women: Why female leaders remain rare on medicine's road less travelled
Kiran Mazumdar-Shaw retires from Infosys board
Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn
Bold bet! Biocon Biologics buys Viatris biosimilars assets for $3.33 billion
Covid-19 put spotlight on vaccines, diagnostics: Mazumdar-Shaw
Covid-19 is an endemic, not pandemic: Mazumdar-Shaw
Mix and match vaccines, says Kiran Mazumdar-Shaw
Syngene’s winning formula

Syngene’s winning formula

Budget 2021: Research, innovation get a boost
Restart economy sooner than later: Kiran Mazumdar-Shaw